Deciphera Pharmaceuticals LLC Pharmaceuticals Healthcare Deals and Alliances...
SummaryDeciphera Pharmaceuticals LLC Deciphera Pharmaceuticals is a research and development company that develops designs and commercializes kinase inhibiting drugs. The company's clinical pipeline of...
View Article'Fears Allayed' by Latest Infliximab Biosimilar Evidence
The biosimilar is noninferior to the originator infliximab in patients with stable Crohn's disease ulcerative colitis and other inflammatory conditions two studies demonstrate. Medscape Medical News
View ArticleNew RealWorld Analyses Support Effectiveness and Safety of Entyvio for...
NewsData showcased at Digestive Disease Week DDW 2017 meeting include presentations of new analyses from the VICTORY consortium.Contributed
View ArticleAbbVie Announces Positive Phase II Study Results For Upadacitinib ABT494 An...
Life Sciences Jobs ...
View ArticleWhat's the best way for patients with inflammatory bowel disease to address...
Wiley When researchers analyzed published studies on how to treat recurrent abdominal pain among patients with inflammatory bowel disease which includes Crohn's disease and ulcerative colitis stress...
View ArticleMICROBIOTE INTESTINAL La protine de soja pour apaiser l'inflammation Journal...
Colite ulcéreuse ou maladie de Crohn sont caractérisées par une inflammation chronique ou périodique du côlon et représentent un facteur...
View ArticleStress management may be promising strategy to treat abdominal pain in IBD...
When researchers analyzed published studies on how to treat recurrent abdominal pain among patients with inflammatory bowel disease which includes Crohn's disease and ulcerative colitis stress...
View ArticleWhat's the best way for patients with inflammatory bowel disease to address...
When researchers analyzed published studies on how to treat recurrent abdominal pain among patients with inflammatory bowel disease which includes Crohn's disease and ulcerative colitis stress...
View ArticleWhats the Best Way for Patients with Inflammatory Bowel Disease to Address...
When researchers analyzed published studies on how to treat recurrent abdominal pain among patients with inflammatory bowel disease which includes Crohns disease and ulcerative colitis stress...
View ArticleResearchers uncover key role for microRNA in inflammatory bowel disease
An international team of researchers has discovered that a microRNA produced by certain white blood cells can prevent excessive inflammation in the intestine. The study "Myeloidderived miR223 regulates...
View ArticleKey role for microRNA in inflammatory bowel disease
An international team of researchers has discovered that a microRNA produced by certain white blood cells can prevent excessive inflammation in the intestine. The study shows that synthetic versions of...
View ArticleAbbVie Announces Positive Phase 2 Study Results for Upadacitinib ABT494 an...
NORTH CHICAGO Ill. May 9 2017 PRNewswire AbbVie NYSE ABBV a global biopharmaceutical company today announced promising results from CELEST a Phase 2 randomized doubleblind placebocontrolled study...
View ArticleArena Pharmaceuticals Provides Corporate Update and Reports First Quarter...
SAN DIEGO May 9 2017 PRNewswire Arena Pharmaceuticals Inc. Nasdaq ARNA a biopharmaceutical company focused on developing novel small molecule drugs across multiple therapeutic areas today provided a...
View ArticleAnother JAK1 Inhibitor Performs Well in Crohn's Disease CMECE
MedPage Today Good results in phase II trial for ABT494
View ArticleTiGenix to present at the Crohn's and Colitis Foundation's Novel Technologies...
PRESS RELEASE TiGenix to present at the Crohn's and Colitis Foundation's Novel Technologies in Inflammatory Bowel Disease workshop in New York Leuven BELGIUM May 10 2017 0700h CEST TiGenix NV Euronext...
View ArticleGenentech Provides Update on Phase III Study of TECENTRIQ Atezolizumab in...
IMvigor211 study did not meet its primary endpoint of overall survival OS compared to chemotherapy The safety profile was consistent with what has been previously observed for TECENTRIQ Genentech a...
View ArticleAbbVies ABT494 demonstrates positive outcome in Phase II trial for Crohn's...
AbbVie has reported positive results from the Phase II CELEST clinical trial of upadacitinib ABT494 for the treatment of patients with Crohn's disease.
View ArticleTrigger for autoimmune disease identified
National Jewish Health Researchers at National Jewish Health have identified a trigger for autoimmune diseases such as lupus Crohn's disease and multiple sclerosis. The findings help explain why women...
View ArticleAbbVie's JAK1 inhibitor hits the mark in Crohn's disease
A Phase 2 study showed upadacitinib significantly reduced patients&39; intestinal inflammation results that should push the drug into latestage testing.
View ArticleAbbVie Presents Positive MidStage Results for its Investigational...
NORTH CHICAGO Ill. May 9 2017 PRNewswire &8212; AbbVie NYSE ABBV a global biopharmaceutical company today announced promising results from CELEST a Phase 2 randomized doubleblind placebocontrolled...
View Article